The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move to bolster operational expertise in precision medicine, Sera Prognostics (SERA) announced the appointment of Mark Capone, former CEO of Myriad Genetics, to its Board of Directors. The appointment aims to accelerate the adoption of the company's PreTRM test for preterm birth risk, the company stated.
The decision comes as Sera Prognostics faces a significant revenue decline and financial headwinds, according to earlier reports. Capone brings extensive experience in commercializing diagnostic solutions, which could help refocus the company's commercial strategy. SERA stock closed at $1.82 on June 30, 2026, trading between $1.77 and $1.92 during the session, per market data.
Investors are watching for whether the appointment will improve the commercial performance of the PreTRM test. With no near-term catalysts on the economic calendar, the market may focus on revenue updates in upcoming quarterly reports as a key indicator of the success of the new strategy.
Sign in to access this content
Sign In